Renal Cell Cancer Update

For this special edition of Oncology Today, I met with Dr Susan Domchek from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayBreastPARP20).

For this special edition of Oncology Today, I met with Dr Srdan Verstovsek from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research in the management of myeloproliferative neoplasms. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMPN20).

For this special edition of Oncology Today, I met with Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts to discuss recently published and emerging research in the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayEGFRNSCLC20).

For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTMM20).

For this special edition of Oncology Today, I met with Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle to discuss recently published and emerging research on the use of immunotherapy in the management of urothelial bladder carcinoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayUBCImmuno20).

For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research including the use of the immune checkpoint inhibitors cemiplimab and pembrolizumab in the management of cutaneous squamous cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaycSCC20).

For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC. CME information and select publications here (https://www.researchtopractice.com/OncologyTodaySCLC20).

For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayFL20).

Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD. CME information and select publications here (http://m.researchtopractice.com/OncologyTodayCRC20).

Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic. RTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/ Additional Resources Calabro L et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8(6):542-4. Abstract (https://pubmed.ncbi.nlm.nih.gov/32278368/) Dingemans AC et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020;15(7):1119-36. Abstract (https://pubmed.ncbi.nlm.nih.gov/32422364/) Di Noia V et al. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: The spark that ignites the fire? Lung Cancer 2020;145:208-10. Abstract (https://pubmed.ncbi.nlm.nih.gov/32439211/) Singh AP et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract 2020:OP2000286. Abstract (https://pubmed.ncbi.nlm.ni

Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. Additional Resources * Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-27. Full text (https://www.nejm.org/doi/full/10.1056/NEJMoa1903387?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) * Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13. Abstract (https://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2403) * Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. Correspondence (https://www.nejm.org/doi/full/10.1056/NEJMc1107627?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) * Von Hoff DD et al

Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2. Additional Resources Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract (https://immunology.sciencemag.org/content/5/48/eabd0110) AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release (https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html)]. April 14, 2020. Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract (https://clincancerres.aacrjournals.org/content/early/2020/04/28/1078-0432.CCR-20-1427) COVID-19 and CLL: Frequently Asked Questions. Hematology.org (http

Oncology nurse practitioner Kelly Goodwin discusses current treatment practices at Massachusetts General Hospital, the challenges encountered treating patients with cancer during COVID-19, and the use of telemedicine in oncology care. Additional Resources Catlin N. Navigating the COVID-19 pandemic as an oncology nurse. Oncology Times 2020;42(8):1,12,17. https://journals.lww.com/oncology-times/Fulltext/2020/04200/ProtectingCancerPatientsDuringthe_Coronavirus.1.aspx (https://journals.lww.com/oncology-times/Fulltext/2020/04200/Protecting_Cancer_Patients_During_the_Coronavirus.1.aspx) Paterson C et al. Oncology nursing during a pandemic: Critical reflections in the context of COVID-19. Semin Oncol Nurs 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177078/) Pelin C et al. Safety at the time of the COVID-19 pandemic: How to keep our oncology patients and healthcare workers safe. J Natl Compr Canc Netw 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/3

Dr Benjamin Levy from Johns Hopkins comments on changes to the surgical and targeted treatment of lung cancer during COVID-19 and challenges in the management of immune-related adverse events with immune checkpoint inhibitors. RTP Lung Cancer Summit Presentations (https://www.researchtopractice.com/LungCancerSummit20/) Additional Resources * Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2). Abstract (https://pubmed.ncbi.nlm.nih.gov/32245904/) Kumar S et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32360578) Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract (https://p

Dr Kathleen Moore from the Stephenson Cancer Cetner and co-chair of the SGO 2020 Annual Meeting discusses COVID guidelines and the impact of the pandemic on clinical research and the treatment of ovarian cancer. Akladios C et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN Group for the CNGOF. J Gynecol Obstet Hum Reprod 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32247066) Dowdy S, Fader AN. Surgical considerations for gynecologic oncologists during the COVID-19 pandemic. SGO 2020. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/surgical-considerations-for-gynecologic-oncologists-during-the-covid-19-pandemic/ Monk B et al. COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32370991/) Mueller B. Telemedicine arrives in the UK: '10 years of

Dr Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance, reviews how telemedicine and the screening, diagnosis and treatment of breast cancer have rapidly adapted based on resource limitations and risk factors related to COVID-19. Additional Resources * Soran A et al. Breast cancer diagnosis, and follow-up during COVID-19 pandemic. Eur J Health 2020;16(2):86-8. Abstract (https://pubmed.ncbi.nlm.nih.gov/32285027/) * American College of Surgeons. COVID-19 guidelines for triage of breast cancer patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer * Falandry C et al. Challenges with the management of older patients with cancer during the COVID-19 pandemic. J Geriatri Oncol 2020;[Online ahead of print]. Abstract (https://www.sciencedirect.com/science/article/pii/S1879406820301533)

Dr Leora Horn of Vanderbilt University Medical Center discusses outcomes for patients with lung cancer and COVID-19 as well as the human implications of social distancing. Additional Resources * AACR Virtual Annual Meeting I: April 27-28, 2020. (https://aacr20.onlineeventpro.freeman.com/) * COVID-19 and Cancer. AACR 2020. Session (https://aacr20.onlineeventpro.freeman.com/live-stream/15335630/COVID-19-and-Cancer) * Garassino, MC. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. AACR 2020. Abstract (https://www.abstractsonline.com/pp8/#!/9045/presentation/10927) * Minello A. The pandemic and the female academic. Nature 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32303729)

Dr Harold Burstein discusses how breast cancer is currently being managed at the Dana-Farber Cancer Institute with the constraints of social distancing and other COVID-19 considerations. COVID-19-Related Resources in Breast Cancer Dietz JR et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020;[Online ahead of print]. Abstract (https://link.springer.com/article/10.1007/s10549-020-05644-z) Braunstein LZ et al. Breast radiotherapy under COVID-19 pandemic resource constraints —Approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States. Adv Radiat Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32292842) Coles CE et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 2020;32(5):279-81. https://www.clinicaloncologyonline.net/article/S0

In this second episode of our new podcast series, Dr Tom Lynch, who began his position as director of the Fred Hutchinson Cancer Research Center as Seattle became the first epicenter of the COVID-19 pandemic in the United States, comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. Additional resources: * Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39. Abstract (https://pubmed.ncbi.nlm.nih.gov/15118073/) * AstraZeneca. [Osimertinib] Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer [press release (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be

On this inaugural episode of our new podcast series, we address the treatment of prostate cancer in the era of COVID-19. Featuring interviews with Drs Neeraj Agarwal, Emmanuel Antonarakis and A Oliver Sartor. Additional Resources * National Comprehensive Cancer Network (NCCN®). Recommendations of the NCCN: Management of prostate cancer during the COVID-19 pandemic. COVID-19 NCCN guidelines (https://2013researchtopractice.cmail19.com/t/y-l-udbbt-trkrhkyuui-b/). * Ueda M et al. Managing cancer care during the COVID-19 pandemic: Agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020;18(4):366-9. Abstract (https://2013researchtopractice.cmail19.com/t/y-l-udbbt-trkrhkyuui-f/)